A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

515

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

DRUG: Odronextamab

Sponsor

Regeneron Pharmaceuticals